Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03476369 · ClinicalTrials.gov registry record · Phase 4
Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention
A Phase 4 study, sponsored by The Guthrie Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
NCT03476369: Clinical Trial Phase 4 study, sponsored by The Guthrie Clinic.
NCT03476369 is a Phase 4 study that was terminated before completion, run by The Guthrie Clinic. The registered enrollment target is 45 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03476369, a Phase 4 study, was terminated before completion, sponsored by The Guthrie Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
Study Summary
During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has demonstrated the decrease in effectiveness of Ticagrelor when administered along with Fentanyl. Hence this study was designed to further assess the interaction between crushed vs non crushed Ticagrelor and Fentanyl given during PCI procedures.
Primary Outcome
The Platelet Function Testing assay will be VerifyNow Platelet Reactivity Assay which is used institutionally. Results are reported in platelet reactive units (PRUs). Based on previous studies, 208 will be used as an estimated cutoff to distinguish therapeutic and subtherapeutic platelet inhibition, with PRUs equal to or less than 208 being considered therapeutic
Interventions
- DRUG Fentanyl
- DRUG Ticagrelor 90Mg Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2025-01-23 |
| Phase | Phase 4 |
Why NCT03476369 stopped before completion
NCT03476369 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Fentanyl is the first listed.
NCT03476369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03476369 about?
NCT03476369 is a clinical study titled "Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention". During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI. However, a recent study has demonstrated the decrease in effectiveness of Ticagrelor when administered along with Fentanyl. Hence this study...
What is the current status of trial NCT03476369?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2018-04-18. Estimated completion is 2025-01-23.
What interventions are being tested in trial NCT03476369?
The interventions under investigation include: Fentanyl (DRUG), Ticagrelor 90Mg Tablet (DRUG).
Who is sponsoring clinical trial NCT03476369?
This trial is sponsored by The Guthrie Clinic, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03476369's enrollment target sits among peer trials
45 1354th of 2000 higher than 638 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI